HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

YCBD

cbdMD, Inc. (AMEX)

Healthcare — Drug Manufacturers - Specialty & Generic

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and hemp-derived solutions under the Herbal Oasis brand. It serves retailers, and health and pet channels through the direct-to-consumer channel, e-commerce platforms, online marketplaces, and wholesale distribution. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is based in Charlotte, North Carolina.

None 1 analysts
$0.57
+ (+0.38%)
Target: $2.00 (250.9%)
Sign in to add YCBD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$7.14M
P/E Ratio (TTM)0.28
Forward P/E-0.76
EPS (TTM)$2.46
Dividend Yield-
Profit Margin-13.29%
Revenue Growth18.80%
ROE-53.39%
Debt/Equity4.47
Recommendation None
Analyst Target$2.00
Analysts1
Indexes AMEX

Technical Indicators

RSI (14)47.5
Beta2.13
SMA 20-
SMA 40-
52-Week High$2.56
52-Week Low$0.47
50-Day Avg$0.78
200-Day Avg$0.87
Avg Volume969.4K
Volume70.1K

Performance Analysis

NEUTRAL

YCBD presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.47), which could present a value opportunity.
~ RSI at 47.5 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ P/E of 0.3 suggests the stock may be undervalued.
~ Modest revenue growth of 18.8% year-over-year.
- Operating at a loss with -13.3% margin.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $2.00 implies 250.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:38 UTC

Back to Screener Export Report